Skip to content
March 29, 2024

Equity.Guru

Investment information for the new generation

Search

biotech

Cybin’s (CYBN.NE) subsidiary Adelia Therapeutics completed earnout milestones originally set in a contribution agreement for the period of January 1, 2021, following Cybin’s acquisition of Adelia. There are a…
XPhyto (XPHY.C) has successfully completed their corporate rebranding and launched a new website. “The company is excited to introduce a fresh look at such a pivotal point in our…
Cannabis hard tablet IP holder Canntab Therapeutics (PILL.C) continues to send product to market, announcing Wednesday they’ve fulfilled 80% of their contract with Medipharm Labs (LABS.T), bringing in another…
Perimeter Medical Imaging AI (PINK.V) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) today for their Optical Coherence Tomography (OCT) imaging system, according to a press…
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million…
Mydecine Innovations Group (MYCO.C) expanded their relationship with Applied Pharmaceutical Innovation (API) to include the University of Alberta in support of multiple drug development and clinical trials, according to…
In 25% of Breast Lumpectomy surgeries, cancerous material is left behind. With current technology, the surgeon needs to wait about a week, to see if he’s got all the cancerous…
Mother nature   Am I a true hippy, or do I have an impulsive personality that morphs and changes due to a lack of identity?   My therapist thinks…
I’ve made no secret of the fact that the Canadian cannabis market frequently annoys the hell out of me. What I want is for it to be a mature…
Buckle up everyone, and get excited – let’s break down Medexus’ latest press release with all its technical details. This is a two-parter, because Medexus not only has closed…